We face some of the most difficult challenges in genomic research for mental disorders. This demands innovation. At Systasy, we have a new visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.
Establishment of a multiparametric safety profiling assay to assess target selectivity and physiological pathway effects of neuroleptics in living cells
Profiling in iPSCs
Establishment of a profiling tool for induced pluripotent stem cells (IPSCs) and cell types differentiated thereof
Establishment of a GPCR screening tool for inverse agonists and testing of a compound toolbox. Collaboration with University of Jena, Institute for Organic Chemstry and Macromolecular Chemistry, providing novel compounds.
First coumpound screen that used the splitSENSOR technology published
SplitSENSOR-based screening of repurposed drugs identified spironolactone as antagonist of ERBB4, a schizophrenia risk gene. In a mouse model of schizophrenia, spironolactone improved relevant endophenotypes in these mice, sparking the initiation of clinical study to assess effectiveness of spironolactone in schizophrenic patients.
Partners in European Marie Curie ITN Network – PDZnet Development of genetic screening tools assessing PDZ protein function in neuronal signalling pathways and PDZ protein interactions to explore therapeutic potential.
Licensing of Systasy’s splitSENSOR patent to Boehringer Ingelheim Systasy Bioscience announces non-exclusive licence agreement with Boehringer Ingelheim forsplitSENSOR assays.
Development of a GPCR profiling tool.
The tool monitors GPCR activities by combining splitSENSOR assays and molecular barcodes as readouts
First products and services sold
Establishment and transfer of an ERBB4 acitvity assay to screen a large compound library for ERBB4 modulators.
Founded in Munich in July 2012 as spin OFF from the Max Planck Institute of Experimental Medicine, Göttingen.
Funding for promoting concepts and products/services to establish Systasy Bioscience GmbH.
BMBF awarded the Validierungs-förderung VIP+ Grant to the laboratory of the Founder Prof. Moritz Rossner for the development of EXTassay – an EXT-based technology platform for highly-parallel drug analysis